id,conversation_id,created_at,date,time,timezone,user_id,username,name,place,tweet,language,mentions,urls,photos,replies_count,retweets_count,likes_count,hashtags,cashtags,link,retweet,quote_url,video,thumbnail,near,geo,source,user_rt_id,user_rt,retweet_id,reply_to,retweet_date,translate,trans_src,trans_dest
1385699529769459713,1385699529769459713,2021-04-24 02:28:07 IST,2021-04-24,02:28:07,+0530,102754598,johncendpts,John Carroll,,This business over $JNJ just looks like fumbling and indecisiveness to me. There needs to be a fundamental review of how this was all handled and a handbook on future pandemics. How long before we're back at this?,en,[],[],[],0,0,3,[],['jnj'],https://twitter.com/JohnCendpts/status/1385699529769459713,False,,0,,,,,,,,[],,,,
1385690008124723207,1385690008124723207,2021-04-24 01:50:17 IST,2021-04-24,01:50:17,+0530,102754598,johncendpts,John Carroll,,ADC Ther­a­peu­tics nabs its first ap­proval as FDA of­fers a quick OK for its DL­B­CL can­cer treat­ment $ADCT  https://t.co/DjXREmITQZ,en,[],['https://endpts.com/adc-therapeutics-nabs-its-first-approval-as-fda-offers-a-quick-ok-for-its-dlbcl-cancer-treatment/'],[],0,1,2,[],['adct'],https://twitter.com/JohnCendpts/status/1385690008124723207,False,,0,,,,,,,,[],,,,
1385664558501556229,1385664558501556229,2021-04-24 00:09:09 IST,2021-04-24,00:09:09,+0530,102754598,johncendpts,John Carroll,,"@ZacharyBrennan has the story -- Roche, Bris­tol My­ers, and Mer­ck prep de­fense for 6 ‘dan­gling’ PD-1 ac­cel­er­at­ed ap­provals, even though they failed con­fir­ma­to­ry tri­als  https://t.co/22irtUbNcr",en,[],['https://endpts.com/roche-bristol-myers-and-merck-prep-defense-for-6-dangling-pd-1-accelerated-approvals-even-though-they-failed-confirmatory-trials/'],[],0,1,0,[],[],https://twitter.com/JohnCendpts/status/1385664558501556229,False,,0,,,,,,,,[],,,,
1385555011883528193,1385555011883528193,2021-04-23 16:53:51 IST,2021-04-23,16:53:51,+0530,102754598,johncendpts,John Carroll,,"Nothing wrong. They bet the farm and won. In this biz, you follow the science and you follow the money. We cover the waterfront of biotech. The whole waterfront",en,[],[],[],1,0,10,[],[],https://twitter.com/JohnCendpts/status/1385555011883528193,False,https://twitter.com/BarbaraWeber7/status/1385408616803483649,0,,,,,,,,[],,,,
1385369530352820225,1385369530352820225,2021-04-23 04:36:49 IST,2021-04-23,04:36:49,+0530,102754598,johncendpts,John Carroll,,What a fiasco.   https://t.co/5e0sWx4Kh6,en,[],['https://www.nytimes.com/2021/04/22/us/politics/johnson-and-johnson-vaccine.html?action=click&module=Top%20Stories&pgtype=Homepage'],[],4,1,12,[],[],https://twitter.com/JohnCendpts/status/1385369530352820225,False,,0,,,,,,,,[],,,,
1385346014945505281,1385346014945505281,2021-04-23 03:03:23 IST,2021-04-23,03:03:23,+0530,102754598,johncendpts,John Carroll,,"So $GSK is estimating PD-1 cost at $15,000 a month, significantly higher than others on the market. What's up with that?",en,[],[],[],3,6,13,[],['gsk'],https://twitter.com/JohnCendpts/status/1385346014945505281,False,,0,,,,,,,,[],,,,
1385344602249469955,1385344602249469955,2021-04-23 02:57:46 IST,2021-04-23,02:57:46,+0530,102754598,johncendpts,John Carroll,,Price of latest PD-1 -- $10K per 500 mg vial  https://t.co/kiIDyYPyzs,en,[],['https://endpts.com/glaxosmithkline-hustles-the-7th-pd-1-past-the-finish-line-in-jemperli-but-how-big-will-uptake-be/'],[],1,0,5,[],[],https://twitter.com/JohnCendpts/status/1385344602249469955,False,,0,,,,,,,,[],,,,
1385338146318032896,1385338146318032896,2021-04-23 02:32:07 IST,2021-04-23,02:32:07,+0530,102754598,johncendpts,John Carroll,,"Maybe Pfizer and Merck KGaA could start with Bavencio, as the worst of the bunch. Besides, Pfizer is making a fortune off its vaccine this year.",en,[],[],[],0,0,5,[],[],https://twitter.com/JohnCendpts/status/1385338146318032896,False,https://twitter.com/bradloncar/status/1385336393241669635,0,,,,,,,,[],,,,
1385335121696362496,1385335121696362496,2021-04-23 02:20:05 IST,2021-04-23,02:20:05,+0530,102754598,johncendpts,John Carroll,,This is new. #7 Glax­o­SmithK­line hus­tles the 7th PD-1 past the fin­ish line with Jem­per­li. But how big will up­take be?  https://t.co/kiIDyYPyzs,en,[],['https://endpts.com/glaxosmithkline-hustles-the-7th-pd-1-past-the-finish-line-in-jemperli-but-how-big-will-uptake-be/'],[],1,0,4,[],[],https://twitter.com/JohnCendpts/status/1385335121696362496,False,,0,,,,,,,,[],,,,
1385334347020922882,1385334347020922882,2021-04-23 02:17:01 IST,2021-04-23,02:17:01,+0530,102754598,johncendpts,John Carroll,,Look for the cat closeup! I hope this goes viral.,en,[],[],[],0,0,3,[],[],https://twitter.com/JohnCendpts/status/1385334347020922882,False,https://twitter.com/jaybradner/status/1385332840733237253,0,,,,,,,,[],,,,
1385333675777093635,1385333675777093635,2021-04-23 02:14:21 IST,2021-04-23,02:14:21,+0530,102754598,johncendpts,John Carroll,,"And -- @ka_blankenship second piece in the package: Ear­ly Zymer­gen in­vestor Jen­ny Rooke re­flects on 'chimeras' in biotech, what it takes to spot a $500M gem  https://t.co/ywcLKCYRtt",en,"[{'screen_name': 'ka_blankenship', 'name': 'kyle blankenship', 'id': '831724003505139712'}]",['https://endpts.com/early-zymergen-investor-jenny-rooke-reflects-on-chimeras-in-biotech-what-it-takes-to-spot-a-500m-gem/'],[],0,0,0,[],[],https://twitter.com/JohnCendpts/status/1385333675777093635,False,,0,,,,,,,,[],,,,
1385333494767751171,1385333494767751171,2021-04-23 02:13:38 IST,2021-04-23,02:13:38,+0530,102754598,johncendpts,John Carroll,,"Next - As Mod­er­na rose, Flag­ship cashed in for $1.4B — with a lot more wealth still re­main­ing  https://t.co/irXvoQrXbe",en,[],['https://endpts.com/as-moderna-rose-flagship-cashed-in-for-1-4b-with-a-lot-more-wealth-still-remaining/'],[],0,1,2,[],[],https://twitter.com/JohnCendpts/status/1385333494767751171,False,,0,,,,,,,,[],,,,
1385333318174969858,1385333318174969858,2021-04-23 02:12:55 IST,2021-04-23,02:12:55,+0530,102754598,johncendpts,John Carroll,,"Followed by: Zymer­gen's bid to dis­rupt a $3T in­dus­tri­al man­u­fac­tur­ing mar­ket goes vi­ral, earn­ing a mas­sive $500M IPO BY @ka_blankenship   https://t.co/xKHFRSeQc5",en,"[{'screen_name': 'ka_blankenship', 'name': 'kyle blankenship', 'id': '831724003505139712'}]",['https://endpts.com/zymergens-bid-to-disrupt-a-3t-industrial-manufacturing-market-goes-viral-earning-a-massive-500m-ipo/'],[],0,1,0,[],[],https://twitter.com/JohnCendpts/status/1385333318174969858,False,,0,,,,,,,,[],,,,
1385333063660425220,1385333063660425220,2021-04-23 02:11:55 IST,2021-04-23,02:11:55,+0530,102754598,johncendpts,John Carroll,,"Still cruising at the top of the charts today: As fears mount over J&amp;J and As­traZeneca, No­vavax en­ters a shaky spot­light By @Jasonmmast   https://t.co/NJsgwyCS2S",en,"[{'screen_name': 'jasonmmast', 'name': 'jason mast', 'id': '560452753'}]",['https://endpts.com/as-fears-mount-over-jj-and-astrazeneca-novavax-enters-a-shaky-spotlight/'],[],0,1,2,[],[],https://twitter.com/JohnCendpts/status/1385333063660425220,False,,0,,,,,,,,[],,,,
1385322126714957826,1385322126714957826,2021-04-23 01:28:27 IST,2021-04-23,01:28:27,+0530,102754598,johncendpts,John Carroll,,"Somewhere out there, the Gods are laughing. What's the housing market look like in the Turks and Caicos islands hese days? -- Biden Eyeing Capital Gains Tax as High as 43.4% for Wealthy  https://t.co/YdtETuHsXP",en,[],['https://www.bloomberg.com/news/articles/2021-04-22/biden-to-propose-capital-gains-tax-as-high-as-43-4-for-wealthy'],[],4,0,11,[],[],https://twitter.com/JohnCendpts/status/1385322126714957826,False,,0,,,,,,,,[],,,,
1385313649187647490,1385313649187647490,2021-04-23 00:54:46 IST,2021-04-23,00:54:46,+0530,102754598,johncendpts,John Carroll,,"Really cool convo just now on digital endpoints. Lots of limitations, but growing. Wonder where we'll be in 5 years? We'll have the recording archived and up in an hour if you want to check it out later",en,[],[],[],0,0,6,[],[],https://twitter.com/JohnCendpts/status/1385313649187647490,False,,0,,,,,,,,[],,,,
1385284128153554946,1385284128153554946,2021-04-22 22:57:28 IST,2021-04-22,22:57:28,+0530,102754598,johncendpts,John Carroll,,"The mantra in the industry is patients, patients, patients. But the unspoken model is slip it by regulators as quick as you can, delay the confirmatory as long as you can and make as much money as possible whenever you can. Should have an experimental price for these drugs $BIIB",en,[],[],[],1,3,30,[],['biib'],https://twitter.com/JohnCendpts/status/1385284128153554946,False,,0,,,,,,,,[],,,,
1385277395716894722,1385277395716894722,2021-04-22 22:30:43 IST,2021-04-22,22:30:43,+0530,102754598,johncendpts,John Carroll,,"An hour away from discussing digital biomarkers with top R&amp;D execs from Duke, J&amp;J, Roche and Pfizer. If that sounds like fun, tune in --  https://t.co/gjBhkNlToK",en,[],['https://webinars.endpts.com/developing-and-using-digital-biomarkers/'],[],0,2,4,[],[],https://twitter.com/JohnCendpts/status/1385277395716894722,False,,0,,,,,,,,[],,,,
1385257542587088900,1385257542587088900,2021-04-22 21:11:49 IST,2021-04-22,21:11:49,+0530,102754598,johncendpts,John Carroll,,"Oh, no, not cheap. $BIIB is in a fix, and everyone knows it. They need more money to make up for the slide underway.",en,[],[],[],2,1,4,[],['biib'],https://twitter.com/JohnCendpts/status/1385257542587088900,False,https://twitter.com/RayTruant/status/1385257268074139648,0,,,,,,,,[],,,,
1385256486524186624,1385256486524186624,2021-04-22 21:07:37 IST,2021-04-22,21:07:37,+0530,102754598,johncendpts,John Carroll,,Maybe the bigger question is how many desperate patients will demand it. The other side of Alzheimer's is oblivion. You are what you remember.,en,[],[],[],2,2,9,[],[],https://twitter.com/JohnCendpts/status/1385256486524186624,False,https://twitter.com/RayTruant/status/1385252361887698952,0,,,,,,,,[],,,,
1385247649654206471,1385247649654206471,2021-04-22 20:32:30 IST,2021-04-22,20:32:30,+0530,102754598,johncendpts,John Carroll,,"Thanks Derek, @Jasonmmast did a great piece. Appreciate the shout outs",en,"[{'screen_name': 'jasonmmast', 'name': 'jason mast', 'id': '560452753'}]",[],[],0,0,4,[],[],https://twitter.com/JohnCendpts/status/1385247649654206471,False,https://twitter.com/Dereklowe/status/1385247025340559361,0,,,,,,,,[],,,,
1385240253623988235,1385240253623988235,2021-04-22 20:03:07 IST,2021-04-22,20:03:07,+0530,102754598,johncendpts,John Carroll,,"And Noubar joins the Covid billionaires club at $MRNA. Bancel, Langer, Springer.  As Mod­er­na rose, Flag­ship cashed in for $1.4B — with a lot more wealth still re­main­ing  https://t.co/irXvoQrXbe",en,[],['https://endpts.com/as-moderna-rose-flagship-cashed-in-for-1-4b-with-a-lot-more-wealth-still-remaining/'],[],2,0,6,[],['mrna'],https://twitter.com/JohnCendpts/status/1385240253623988235,False,,0,,,,,,,,[],,,,
1385229193605095435,1385229193605095435,2021-04-22 19:19:10 IST,2021-04-22,19:19:10,+0530,102754598,johncendpts,John Carroll,,"$VRTX is one of the most interesting R&amp;D partners now in play... Ver­tex adds a new gene edit­ing part­ner, pay­ing Ob­sid­i­an $75M for con­trol­lable CRISPR sys­tem  https://t.co/51cJuQkkq7",en,[],['https://endpts.com/vertex-adds-a-new-gene-editing-partner-paying-obsidian-75m-cash-for-controllable-crispr-system/'],[],1,6,9,[],['vrtx'],https://twitter.com/JohnCendpts/status/1385229193605095435,False,,0,,,,,,,,[],,,,
1385225352977403904,1385225352977403904,2021-04-22 19:03:55 IST,2021-04-22,19:03:55,+0530,102754598,johncendpts,John Carroll,,"Damn the crit­ics, Bio­gen CEO Vounatsos or­ders full speed ahead on prep­ping a con­tro­ver­sial ad­u­canum­ab launch as FDA de­ci­sion looms $BIIB  https://t.co/jVrfDUuWPV",en,[],['https://endpts.com/damn-the-critics-biogen-ceo-vounatsos-orders-full-speed-ahead-on-prepping-a-controversial-aducanumab-launch-as-fda-decision-looms/'],[],2,2,3,[],['biib'],https://twitter.com/JohnCendpts/status/1385225352977403904,False,,0,,,,,,,,[],,,,
1385198073589100544,1385198073589100544,2021-04-22 17:15:31 IST,2021-04-22,17:15:31,+0530,102754598,johncendpts,John Carroll,,"All these headlines with $100M IPO filed here and $100M IPO filed there, that's just a placeholder for what's coming. New game, new rules. But for how long?",en,[],[],[],2,1,13,[],[],https://twitter.com/JohnCendpts/status/1385198073589100544,False,,0,,,,,,,,[],,,,
1385196756074258459,1385196756074258459,2021-04-22 17:10:17 IST,2021-04-22,17:10:17,+0530,102754598,johncendpts,John Carroll,,"Zymer­gen's bid to dis­rupt a $3T in­dus­tri­al man­u­fac­tur­ing mar­ket goes vi­ral, earn­ing a mas­sive $500M IPO By @ka_blankenship   https://t.co/xKHFRSeQc5",en,"[{'screen_name': 'ka_blankenship', 'name': 'kyle blankenship', 'id': '831724003505139712'}]",['https://endpts.com/zymergens-bid-to-disrupt-a-3t-industrial-manufacturing-market-goes-viral-earning-a-massive-500m-ipo/'],[],1,1,12,[],[],https://twitter.com/JohnCendpts/status/1385196756074258459,False,,0,,,,,,,,[],,,,
1385193069184569346,1385193069184569346,2021-04-22 16:55:37 IST,2021-04-22,16:55:37,+0530,102754598,johncendpts,John Carroll,,"$BIIB Q1 profit dropped 71%, aducanumab looms larger than ever.",en,[],[],[],0,2,14,[],['biib'],https://twitter.com/JohnCendpts/status/1385193069184569346,False,,0,,,,,,,,[],,,,
1385040417175965696,1385040417175965696,2021-04-22 06:49:02 IST,2021-04-22,06:49:02,+0530,102754598,johncendpts,John Carroll,,"This is the 2,774th anniversary of the founding of Rome by Romulus. Cheers",en,[],[],[],1,1,14,[],[],https://twitter.com/JohnCendpts/status/1385040417175965696,False,,0,,,,,,,,[],,,,
1385017426392223744,1385017426392223744,2021-04-22 05:17:41 IST,2021-04-22,05:17:41,+0530,102754598,johncendpts,John Carroll,,Biotech VCs are having way too much fun. Let the good times roll. I'm all for this.,en,[],[],[],0,0,8,[],[],https://twitter.com/JohnCendpts/status/1385017426392223744,False,https://twitter.com/Nicole_DeFeudis/status/1384445860369641480,0,,,,,,,,[],,,,
1384956135917170691,1384956135917170691,2021-04-22 01:14:08 IST,2021-04-22,01:14:08,+0530,102754598,johncendpts,John Carroll,,#3 from managing editor @ka_blankenship  Ex­clu­sive: Genen­tech's for­mer Tecen­triq 'CEO' jumps ship to head up com­mer­cial at an on­colyt­ic virus play­er  https://t.co/WLaAFCcylL,en,"[{'screen_name': 'ka_blankenship', 'name': 'kyle blankenship', 'id': '831724003505139712'}]",['https://endpts.com/exclusive-genentechs-former-tecentriq-ceo-jumps-ship-to-head-up-commercial-at-an-oncolytic-virus-player/'],[],0,0,0,[],[],https://twitter.com/JohnCendpts/status/1384956135917170691,False,,0,,,,,,,,[],,,,
1384955823617630209,1384955823617630209,2021-04-22 01:12:54 IST,2021-04-22,01:12:54,+0530,102754598,johncendpts,John Carroll,,"#2 is a must-read from the amazing @Jasonmmast -- As fears mount over J&amp;J and As­traZeneca, No­vavax en­ters a shaky spot­light  https://t.co/NJsgwyUtrs",en,"[{'screen_name': 'jasonmmast', 'name': 'jason mast', 'id': '560452753'}]",['https://endpts.com/as-fears-mount-over-jj-and-astrazeneca-novavax-enters-a-shaky-spotlight/'],[],0,2,6,[],[],https://twitter.com/JohnCendpts/status/1384955823617630209,False,,0,,,,,,,,[],,,,
1384955437032804354,1384955437032804354,2021-04-22 01:11:22 IST,2021-04-22,01:11:22,+0530,102754598,johncendpts,John Carroll,,Top 3 today starts with more money: Ver­sant pulls the wraps off of near­ly $1B in 3 new funds out to build the next fleet of biotech star­tups. And this new gen­er­a­tion is built for speed  https://t.co/ZNozizUdyp,en,[],['https://endpts.com/versant-pulls-the-wraps-off-of-nearly-1b-in-3-new-funds-out-to-build-the-next-fleet-of-biotech-startups-and-this-new-generation-is-built-for-speed/'],[],1,0,2,[],[],https://twitter.com/JohnCendpts/status/1384955437032804354,False,,0,,,,,,,,[],,,,
1384925309372452867,1384925309372452867,2021-04-21 23:11:39 IST,2021-04-21,23:11:39,+0530,102754598,johncendpts,John Carroll,,FDA+ report will soon be on its way to subscribers of the report. Join up now.,en,[],[],[],0,0,0,[],[],https://twitter.com/JohnCendpts/status/1384925309372452867,False,,0,,,,,,,,[],,,,
1384923591549067265,1384923591549067265,2021-04-21 23:04:49 IST,2021-04-21,23:04:49,+0530,102754598,johncendpts,John Carroll,,"Hear, hear, quite right.... Law pro­fes­sors call for FDA to dis­close all safe­ty and ef­fi­ca­cy da­ta for drugs by @ZacharyBrennan   https://t.co/Z9BPlxARhD",en,"[{'screen_name': 'zacharybrennan', 'name': 'zach brennan', 'id': '605657704'}]",['https://endpts.com/law-professors-call-for-fda-to-disclose-all-safety-and-efficacy-data-for-drugs/'],[],2,6,6,[],[],https://twitter.com/JohnCendpts/status/1384923591549067265,False,,0,,,,,,,,[],,,,
1384868678458650629,1384868678458650629,2021-04-21 19:26:37 IST,2021-04-21,19:26:37,+0530,102754598,johncendpts,John Carroll,,"FDA of­fers scathing re­view of Emer­gent plan­t's san­i­tary con­di­tions, em­ploy­ee train­ing af­ter halt­ing pro­duc­tion $EBS  https://t.co/VbtTfV6JFw",en,[],['https://endpts.com/fda-raises-serious-concerns-with-emergent-plants-sanitary-conditions-employee-training-in-latest-inspection/'],[],7,10,25,[],['ebs'],https://twitter.com/JohnCendpts/status/1384868678458650629,False,,0,,,,,,,,[],,,,
1384847710839349252,1384847710839349252,2021-04-21 18:03:18 IST,2021-04-21,18:03:18,+0530,102754598,johncendpts,John Carroll,,The top biopharma companies in the world collectively spent more than $40 million in just the first quarter of 2021 on lobbying Congress as part of preparations to stave off major drug pricing legislation that’s expected later this year.  https://t.co/lyPerI4ocz,en,[],['https://endpts.com/biopharma-ramps-up-lobbying-spend-as-drug-pricing-legislation-nears/'],[],2,3,3,[],[],https://twitter.com/JohnCendpts/status/1384847710839349252,False,,0,,,,,,,,[],,,,
1384839630286065664,1384839630286065664,2021-04-21 17:31:11 IST,2021-04-21,17:31:11,+0530,102754598,johncendpts,John Carroll,,New and notable: Alde­vron founders back a biotech start­up that's look­ing to end the moral de­bate over cell lines once and for all  https://t.co/EbN664XAK9,en,[],['https://endpts.com/aldevron-founders-back-a-biotech-startup-thats-looking-to-end-the-moral-debate-over-cell-lines-once-and-for-all/'],[],0,2,5,[],[],https://twitter.com/JohnCendpts/status/1384839630286065664,False,,0,,,,,,,,[],,,,
1384835216506642434,1384835216506642434,2021-04-21 17:13:39 IST,2021-04-21,17:13:39,+0530,102754598,johncendpts,John Carroll,,Ex­clu­sive: Genen­tech's for­mer Tecen­triq 'CEO' jumps ship to head up com­mer­cial at an on­colyt­ic virus play­er By @ka_blankenship   https://t.co/WLaAFCu9dj,en,"[{'screen_name': 'ka_blankenship', 'name': 'kyle blankenship', 'id': '831724003505139712'}]",['https://endpts.com/exclusive-genentechs-former-tecentriq-ceo-jumps-ship-to-head-up-commercial-at-an-oncolytic-virus-player/'],[],2,1,14,[],[],https://twitter.com/JohnCendpts/status/1384835216506642434,False,,0,,,,,,,,[],,,,
1384809389429727235,1384809389429727235,2021-04-21 15:31:01 IST,2021-04-21,15:31:01,+0530,102754598,johncendpts,John Carroll,,I spoke with Brad Bolzon... Ver­sant pulls the wraps off of near­ly $1B in 3 new funds out to build the next fleet of biotech star­tups. And this new gen­er­a­tion is built for speed  https://t.co/ZNozizCC9P,en,[],['https://endpts.com/versant-pulls-the-wraps-off-of-nearly-1b-in-3-new-funds-out-to-build-the-next-fleet-of-biotech-startups-and-this-new-generation-is-built-for-speed/'],[],0,1,8,[],[],https://twitter.com/JohnCendpts/status/1384809389429727235,False,,0,,,,,,,,[],,,,
1384663626871496707,1384663626871496707,2021-04-21 05:51:49 IST,2021-04-21,05:51:49,+0530,102754598,johncendpts,John Carroll,,That's right.,en,[],[],[],0,0,7,[],[],https://twitter.com/JohnCendpts/status/1384663626871496707,False,https://twitter.com/skathire/status/1384661876341186563,0,,,,,,,,[],,,,
1384637703422058508,1384637703422058508,2021-04-21 04:08:48 IST,2021-04-21,04:08:48,+0530,102754598,johncendpts,John Carroll,,"what's the new normal look like from your perspective, Sek? Flex hours? 5 days in the office? remote optional?",en,[],[],[],4,0,7,[],[],https://twitter.com/JohnCendpts/status/1384637703422058508,False,https://twitter.com/skathire/status/1384636575263465474,0,,,,,,,,[],,,,
1384636240809451526,1384636240809451526,2021-04-21 04:02:59 IST,2021-04-21,04:02:59,+0530,102754598,johncendpts,John Carroll,,"What's one of the core tenets of Republican/conservatism? Lower regulatory hurdles for business. Yet citizens of the Republican controlled (great) state of Texas are forced to grapple with an absurd level of expensive, bureaucratic, time-wasting nitpicking. Enough!",en,[],[],[],0,0,5,[],[],https://twitter.com/JohnCendpts/status/1384636240809451526,False,,0,,,,,,,,[],,,,
1384619523257495560,1384619523257495560,2021-04-21 02:56:33 IST,2021-04-21,02:56:33,+0530,102754598,johncendpts,John Carroll,,"this is new: from @JSully27  Bris­tol My­ers adds on at its Cam­bridge Cross­ing R&amp;D hub, set­tling in even fur­ther in bustling Boston area biotech hub  https://t.co/sj9TAu91yL",en,"[{'screen_name': 'jsully27', 'name': 'josh sullivan', 'id': '55707271'}]",['https://endpts.com/bristol-myers-adds-on-at-its-cambridge-crossing-rd-hub-settling-in-even-further-in-bustling-boston-area-biotech-hub/'],[],0,1,12,[],[],https://twitter.com/JohnCendpts/status/1384619523257495560,False,,0,,,,,,,,[],,,,
1384611061593038850,1384611061593038850,2021-04-21 02:22:56 IST,2021-04-21,02:22:56,+0530,102754598,johncendpts,John Carroll,,"I'll guarantee you one thing -- lots more money getting pumped into the biosystem in tomorrow's issue. But then, you probably expected that already.",en,[],[],[],0,0,7,[],[],https://twitter.com/JohnCendpts/status/1384611061593038850,False,,0,,,,,,,,[],,,,
1384610691840036867,1384610691840036867,2021-04-21 02:21:28 IST,2021-04-21,02:21:28,+0530,102754598,johncendpts,John Carroll,,"And we've updated Syndax, which is getting hammered today  on concerns -- $SNDX -31%, ouch  https://t.co/kN7hXlq5Ev",en,[],['https://endpts.com/syndax-looks-to-rebound-from-stinging-late-stage-failure-uncorking-early-data-for-next-cancer-drug-up/'],[],0,1,2,[],['sndx'],https://twitter.com/JohnCendpts/status/1384610691840036867,False,,0,,,,,,,,[],,,,
1384610258933407744,1384610258933407744,2021-04-21 02:19:45 IST,2021-04-21,02:19:45,+0530,102754598,johncendpts,John Carroll,,"#4 has been updated -- UP­DAT­ED: Blue­bird says it has more good news for its gene ther­a­py safe­ty, but a pric­ing dis­agree­ment in Ger­many will spur lay­offs  https://t.co/sB6skTzXTR",en,[],['https://endpts.com/bluebird-says-it-has-more-good-news-for-its-gene-therapy-safety-but-a-pricing-disagreement-in-germany-will-spur-layoffs/'],[],0,1,2,[],[],https://twitter.com/JohnCendpts/status/1384610258933407744,False,,0,,,,,,,,[],,,,
1384609966070263809,1384609966070263809,2021-04-21 02:18:35 IST,2021-04-21,02:18:35,+0530,102754598,johncendpts,John Carroll,,"#3 Chen Yu jumps ship from Vi­vo Cap­i­tal and goes large, al­ly­ing with The Col­umn Group on an in­au­gur­al $824M biotech crossover fund  https://t.co/3IxEQPoFUg",en,[],['https://endpts.com/chen-yu-jumps-ship-from-vivo-capital-and-goes-large-allying-with-the-column-group-on-an-inaugural-824m-biotech-crossover-fund/'],[],0,1,1,[],[],https://twitter.com/JohnCendpts/status/1384609966070263809,False,,0,,,,,,,,[],,,,
1384609756656988161,1384609756656988161,2021-04-21 02:17:45 IST,2021-04-21,02:17:45,+0530,102754598,johncendpts,John Carroll,,#2 -- everybody loves a story involving a certain MIT billionaire scientist MIT’s fa­bled bil­lion­aire sci­en­tist Robert Langer is step­ping in to of­fer a key as­sist to Ovid CEO Je­re­my Levin $OVID  https://t.co/0iocAhQkkH,en,[],['https://endpts.com/mits-fabled-billionaire-scientist-robert-langer-is-stepping-in-to-offer-a-key-assist-to-ovid-ceo-jeremy-levin/'],[],0,2,5,[],['ovid'],https://twitter.com/JohnCendpts/status/1384609756656988161,False,,0,,,,,,,,[],,,,
1384609402439626756,1384609402439626756,2021-04-21 02:16:20 IST,2021-04-21,02:16:20,+0530,102754598,johncendpts,John Carroll,,"@Jasonmmast wrote the most popular story today: UP­DAT­ED: Ver­tex pays CRISPR $900M to take con­trol of sick­le cell part­ner­ship, bet­ting they can beat blue­bird -- and re­new­ing an­a­lyst­s' skep­ti­cism $VRTX  https://t.co/I0sVOH6AZa",en,[],['https://endpts.com/vertex-pays-crispr-900m-to-take-control-of-sickle-cell-partnership-betting-they-can-beat-bluebird-to-market/'],[],0,0,1,[],['vrtx'],https://twitter.com/JohnCendpts/status/1384609402439626756,False,,0,,,,,,,,[],,,,
1384528331836575751,1384528331836575751,2021-04-20 20:54:12 IST,2021-04-20,20:54:12,+0530,102754598,johncendpts,John Carroll,,Of course it's RA.... RA Cap­i­tal leads $125M for Janux in VC's lat­est crossover bid By @Jasonmmast   https://t.co/aXfWNUy7ho,en,"[{'screen_name': 'jasonmmast', 'name': 'jason mast', 'id': '560452753'}]",['https://endpts.com/ra-capital-leads-125m-for-janux-in-vcs-latest-crossover-bid/'],[],1,0,7,[],[],https://twitter.com/JohnCendpts/status/1384528331836575751,False,,0,,,,,,,,[],,,,
1384520259479097348,1384520259479097348,2021-04-20 20:22:07 IST,2021-04-20,20:22:07,+0530,102754598,johncendpts,John Carroll,,"Blue­bird says it has more good news for its gene ther­a­py safe­ty, but a pric­ing dis­agree­ment in Ger­many will spur lay­offs $blue  https://t.co/sB6skTRyLp",en,[],['https://endpts.com/bluebird-says-it-has-more-good-news-for-its-gene-therapy-safety-but-a-pricing-disagreement-in-germany-will-spur-layoffs/'],[],0,0,4,[],['blue'],https://twitter.com/JohnCendpts/status/1384520259479097348,False,,0,,,,,,,,[],,,,
1384517279258271748,1384517279258271748,2021-04-20 20:10:17 IST,2021-04-20,20:10:17,+0530,102754598,johncendpts,John Carroll,,EMA to add safe­ty warn­ing to J&amp;J Covid-19 vac­cine over rare blood clots  https://t.co/AHIEz3PpmW,en,[],['https://endpts.com/ema-to-add-safety-warning-to-jj-covid-19-vaccine-over-rare-but-fatal-blood-clots/'],[],0,0,1,[],[],https://twitter.com/JohnCendpts/status/1384517279258271748,False,,0,,,,,,,,[],,,,
1384514301407371273,1384514301407371273,2021-04-20 19:58:27 IST,2021-04-20,19:58:27,+0530,102754598,johncendpts,John Carroll,,@Jasonmmast updated his $VRTX story after analysts questioned the size of this bet $BLUE  https://t.co/I0sVOH6AZa,en,[],['https://endpts.com/vertex-pays-crispr-900m-to-take-control-of-sickle-cell-partnership-betting-they-can-beat-bluebird-to-market/'],[],0,0,0,[],"['vrtx', 'blue']",https://twitter.com/JohnCendpts/status/1384514301407371273,False,,0,,,,,,,,[],,,,
1384505352117383172,1384505352117383172,2021-04-20 19:22:53 IST,2021-04-20,19:22:53,+0530,102754598,johncendpts,John Carroll,,I asked Bob about this.... MIT’s fa­bled bil­lion­aire sci­en­tist Robert Langer is step­ping in to of­fer a key as­sist to Ovid CEO Je­re­my Levin $OVID  https://t.co/0iocAhQkkH,en,[],['https://endpts.com/mits-fabled-billionaire-scientist-robert-langer-is-stepping-in-to-offer-a-key-assist-to-ovid-ceo-jeremy-levin/'],[],0,1,11,[],['ovid'],https://twitter.com/JohnCendpts/status/1384505352117383172,False,,0,,,,,,,,[],,,,
1384503872681504777,1384503872681504777,2021-04-20 19:17:00 IST,2021-04-20,19:17:00,+0530,102754598,johncendpts,John Carroll,,Am­gen's promis­ing gas­tric can­cer drug makes good on Five Prime po­ten­tial with FDA's break­through nod $AMGN by @JSully27  https://t.co/FcPz4Zd5RL,en,"[{'screen_name': 'jsully27', 'name': 'josh sullivan', 'id': '55707271'}]",['https://endpts.com/amgens-promising-gastric-cancer-drug-makes-good-on-five-prime-potential-with-fdas-breakthrough-nod/'],[],0,1,2,[],['amgn'],https://twitter.com/JohnCendpts/status/1384503872681504777,False,,0,,,,,,,,[],,,,
1384497438325575685,1384497438325575685,2021-04-20 18:51:26 IST,2021-04-20,18:51:26,+0530,102754598,johncendpts,John Carroll,,A top an­a­lyst sees Pfiz­er and Mod­er­na seiz­ing a $38B prize as safe­ty frets side­line glob­al vac­cine play­ers $PFE $MRNA $JNJ $AZN $NVAX  https://t.co/PQ24yqySxj,en,[],['https://endpts.com/a-top-analyst-sees-pfizer-and-moderna-seizing-a-38b-prize-as-safety-frets-sideline-global-vaccine-players/'],[],0,3,22,[],"['pfe', 'mrna', 'jnj', 'azn', 'nvax']",https://twitter.com/JohnCendpts/status/1384497438325575685,False,,0,,,,,,,,[],,,,
1384491599120408591,1384491599120408591,2021-04-20 18:28:14 IST,2021-04-20,18:28:14,+0530,102754598,johncendpts,John Carroll,,"Saman­tha Du's Zai Lab sets its am­bi­tions sky high, look­ing to raise $750M to fu­el its li­cens­ing busi­ness mod­el  https://t.co/oL1bmThuOB",en,[],['https://endpts.com/samantha-dus-zai-lab-sets-its-ambitions-sky-high-looking-to-raise-750m-to-fuel-its-licensing-business-model/'],[],0,3,1,[],[],https://twitter.com/JohnCendpts/status/1384491599120408591,False,,0,,,,,,,,[],,,,
1384485112109170691,1384485112109170691,2021-04-20 18:02:27 IST,2021-04-20,18:02:27,+0530,102754598,johncendpts,John Carroll,,No AAV? No prob­lem. Code Bio­ther­a­peu­tics joins the search for a non-vi­ral gene ther­a­py  https://t.co/5MqFzPJ5Ix,en,[],['https://endpts.com/no-aav-no-problem-code-biotherapeutics-joins-the-search-for-a-non-viral-gene-therapy/'],[],0,1,16,[],[],https://twitter.com/JohnCendpts/status/1384485112109170691,False,,0,,,,,,,,[],,,,
1384469840685985796,1384469840685985796,2021-04-20 17:01:46 IST,2021-04-20,17:01:46,+0530,102754598,johncendpts,John Carroll,,"FDA slaps a hold on KalVis­ta's PhII study of an HAE drug, rais­ing a red flag on pre­clin­i­cal re­sults $KALV  https://t.co/mv15cQ08Nm",en,[],['https://endpts.com/fda-slaps-a-hold-on-kalvistas-phii-study-of-an-hae-drug-raising-a-red-flag-on-preclinical-results/'],[],0,0,0,[],['kalv'],https://twitter.com/JohnCendpts/status/1384469840685985796,False,,0,,,,,,,,[],,,,
1384466134586380297,1384466134586380297,2021-04-20 16:47:03 IST,2021-04-20,16:47:03,+0530,102754598,johncendpts,John Carroll,,"Ver­tex pays CRISPR $900M to take con­trol of sick­le cell part­ner­ship, bet­ting they can beat blue­bird to mar­ket  https://t.co/I0sVOH6AZa",en,[],['https://endpts.com/vertex-pays-crispr-900m-to-take-control-of-sickle-cell-partnership-betting-they-can-beat-bluebird-to-market/'],[],0,12,18,[],[],https://twitter.com/JohnCendpts/status/1384466134586380297,False,,0,,,,,,,,[],,,,
1384463289518759936,1384463289518759936,2021-04-20 16:35:44 IST,2021-04-20,16:35:44,+0530,102754598,johncendpts,John Carroll,,More biotech news coming in 10 minutes,en,[],[],[],3,1,15,[],[],https://twitter.com/JohnCendpts/status/1384463289518759936,False,,0,,,,,,,,[],,,,
1384463106684772358,1384463106684772358,2021-04-20 16:35:01 IST,2021-04-20,16:35:01,+0530,102754598,johncendpts,John Carroll,,"Chen Yu jumps ship from Vi­vo Cap­i­tal and goes large, al­ly­ing with The Col­umn Group on an in­au­gur­al $824M biotech crossover fund  https://t.co/3IxEQPoFUg",en,[],['https://endpts.com/chen-yu-jumps-ship-from-vivo-capital-and-goes-large-allying-with-the-column-group-on-an-inaugural-824m-biotech-crossover-fund/'],[],0,1,17,[],[],https://twitter.com/JohnCendpts/status/1384463106684772358,False,,0,,,,,,,,[],,,,
1384307709835583490,1384307709835583490,2021-04-20 06:17:31 IST,2021-04-20,06:17:31,+0530,102754598,johncendpts,John Carroll,,"I accidentally stumbled across an old war classic -- The Lost Patrol, a John Ford movie from the 1930s, and it's a perfect metaphor for Vietnam or the Middle East wars. Unexpected.",en,[],[],[],0,0,4,[],[],https://twitter.com/JohnCendpts/status/1384307709835583490,False,,0,,,,,,,,[],,,,
1384235613591801873,1384235613591801873,2021-04-20 01:31:02 IST,2021-04-20,01:31:02,+0530,102754598,johncendpts,John Carroll,,Biotech's IPO raise approaches $5.5B as Nasdaq continues to prove fruitful with 2 debuts and three new filings By @MaxGelman  https://t.co/QiO5gufE7I,en,"[{'screen_name': 'maxgelman', 'name': 'max gelman', 'id': '308763219'}]",['https://endpts.com/biotechs-ipo-raise-approaches-5-5b-as-nasdaq-continues-to-prove-fruitful-with-two-debuts-and-three-new-filings/'],[],0,2,1,[],[],https://twitter.com/JohnCendpts/status/1384235613591801873,False,,0,,,,,,,,[],,,,
1384235317092184075,1384235317092184075,2021-04-20 01:29:52 IST,2021-04-20,01:29:52,+0530,102754598,johncendpts,John Carroll,,#2: Tillman Gerngross' Covid-19 antibody moonshot scores $336M with the help of new ace CFO. Is an IPO next? By @ka_blankenship   https://t.co/uf8f9NpVSQ,en,"[{'screen_name': 'ka_blankenship', 'name': 'kyle blankenship', 'id': '831724003505139712'}]",['https://endpts.com/tillman-gerngross-covid-19-antibody-moonshot-scores-336m-with-the-help-of-new-ace-cfo-is-an-ipo-next/'],[],0,0,2,[],[],https://twitter.com/JohnCendpts/status/1384235317092184075,False,,0,,,,,,,,[],,,,
1384235175823896580,1384235175823896580,2021-04-20 01:29:18 IST,2021-04-20,01:29:18,+0530,102754598,johncendpts,John Carroll,,Top 3 today starts with: Recursion founders gin fortunes as IPO backers shower $436M on one of the biggest boasts in AI -- based on some very small deals  https://t.co/cgGS1xgxIA,en,[],['https://endpts.com/recursion-founders-gin-fortunes-as-ipo-backers-shower-436m-on-one-of-the-biggest-boasts-in-ai-based-on-some-very-small-deals/'],[],0,0,0,[],[],https://twitter.com/JohnCendpts/status/1384235175823896580,False,,0,,,,,,,,[],,,,
1384214317034180618,1384214317034180618,2021-04-20 00:06:25 IST,2021-04-20,00:06:25,+0530,102754598,johncendpts,John Carroll,,"3,236 satellites. Plus owning a big chunk of the cloud now for low cost web services. I'd hate to compete with these people. Like walking in front of a freight train",en,[],[],[],4,1,5,[],[],https://twitter.com/JohnCendpts/status/1384214317034180618,False,https://twitter.com/business/status/1384213258073100294,0,,,,,,,,[],,,,
1384163822647218192,1384163822647218192,2021-04-19 20:45:46 IST,2021-04-19,20:45:46,+0530,102754598,johncendpts,John Carroll,,"When's the IPO? Jami Rubin, once fabled for grilling biopharma execs, decamps to head finance at drug pricing disrupter  https://t.co/DJ7f1x8tcF",en,[],['https://endpts.com/jami-rubin-once-fabled-for-grilling-biopharma-execs-decamps-to-head-finance-at-drug-pricing-disrupter/'],[],0,0,2,[],[],https://twitter.com/JohnCendpts/status/1384163822647218192,False,,0,,,,,,,,[],,,,
1384162955495755783,1384162955495755783,2021-04-19 20:42:19 IST,2021-04-19,20:42:19,+0530,102754598,johncendpts,John Carroll,,"Such a weird story -- from @ka_blankenship The doctor is in: Trump insider Ben Carson joins NASH player Galectin as a 'special consultant,' part-time spokesman  https://t.co/uCtvh8Sdx0",en,"[{'screen_name': 'ka_blankenship', 'name': 'kyle blankenship', 'id': '831724003505139712'}]",['https://endpts.com/the-doctor-is-in-trump-insider-ben-carson-joins-nash-player-galectin-as-a-special-consultant-part-time-spokesman/'],[],8,2,6,[],[],https://twitter.com/JohnCendpts/status/1384162955495755783,False,,0,,,,,,,,[],,,,
1384134850744000522,1384134850744000522,2021-04-19 18:50:39 IST,2021-04-19,18:50:39,+0530,102754598,johncendpts,John Carroll,,FDA slaps a hold on Moffitt’s next-gen CAR-T as regulators demand another delay on clinical work — shares crater  https://t.co/gxvwjQgMIN,en,[],['https://endpts.com/fda-slaps-a-hold-on-moffitts-next-gen-car-t-as-regulators-demand-another-delay-on-clinical-work-shares-crater/'],[],0,0,1,[],[],https://twitter.com/JohnCendpts/status/1384134850744000522,False,,0,,,,,,,,[],,,,
1384123236342931458,1384123236342931458,2021-04-19 18:04:29 IST,2021-04-19,18:04:29,+0530,102754598,johncendpts,John Carroll,,"Digital endpoints are all the rage, especially in the Covid era. Check out the upcoming webinar -- it's free to attend.  https://t.co/gjBhkNlToK",en,[],['https://webinars.endpts.com/developing-and-using-digital-biomarkers/'],[],0,0,1,[],[],https://twitter.com/JohnCendpts/status/1384123236342931458,False,,0,,,,,,,,[],,,,
1384107532575141892,1384107532575141892,2021-04-19 17:02:05 IST,2021-04-19,17:02:05,+0530,102754598,johncendpts,John Carroll,,"I'm picturing Kolchinsky and Tillman in the same room, masks off  -- Tillman Gerngross' Covid-19 antibody moonshot scores $336M with the help of new ace CFO. Is an IPO next?  https://t.co/uf8f9NpVSQ",en,[],['https://endpts.com/tillman-gerngross-covid-19-antibody-moonshot-scores-336m-with-the-help-of-new-ace-cfo-is-an-ipo-next/'],[],1,0,6,[],[],https://twitter.com/JohnCendpts/status/1384107532575141892,False,,0,,,,,,,,[],,,,
1384104220844969984,1384104220844969984,2021-04-19 16:48:56 IST,2021-04-19,16:48:56,+0530,102754598,johncendpts,John Carroll,,Along those lines: Biotech's IPO raise approaches $5.5B as Nasdaq continues to prove fruitful with two debuts and three new filings By @MaxGelman  https://t.co/QiO5gufE7I,en,"[{'screen_name': 'maxgelman', 'name': 'max gelman', 'id': '308763219'}]",['https://endpts.com/biotechs-ipo-raise-approaches-5-5b-as-nasdaq-continues-to-prove-fruitful-with-two-debuts-and-three-new-filings/'],[],0,0,1,[],[],https://twitter.com/JohnCendpts/status/1384104220844969984,False,,0,,,,,,,,[],,,,
1384103778866008072,1384103778866008072,2021-04-19 16:47:10 IST,2021-04-19,16:47:10,+0530,102754598,johncendpts,John Carroll,,Q1 biopharma numbers exploded. Is that a good thing?  https://t.co/9GxygoXM3v,en,[],['https://endpts.com/q1-a-flood-of-investor-cash-drove-biotechs-numbers-to-new-record-highs-and-the-torrent-of-cash-is-moving-upstream-fast/'],[],1,1,4,[],[],https://twitter.com/JohnCendpts/status/1384103778866008072,False,,0,,,,,,,,[],,,,
1383465652904595457,1383465652904595457,2021-04-17 22:31:29 IST,2021-04-17,22:31:29,+0530,102754598,johncendpts,John Carroll,,I thought it would be fun to write this up today -- Recursion founders gin fortunes as IPO backers shower $436M on one of the biggest boasts in AI -- based on some very small deals $RXRX  https://t.co/cgGS1xgxIA,en,[],['https://endpts.com/recursion-founders-gin-fortunes-as-ipo-backers-shower-436m-on-one-of-the-biggest-boasts-in-ai-based-on-some-very-small-deals/'],[],0,1,4,[],['rxrx'],https://twitter.com/JohnCendpts/status/1383465652904595457,False,,0,,,,,,,,[],,,,
1383461285065478158,1383461285065478158,2021-04-17 22:14:08 IST,2021-04-17,22:14:08,+0530,102754598,johncendpts,John Carroll,,"#5 Scoop: Ferring, Blackstone’s $570M gene therapy venture has imploded after CMC issues stymied a once high-profile quest  https://t.co/LCCoauXW1p",en,[],['https://endpts.com/scoop-ferring-blackstones-570m-gene-therapy-venture-has-imploded-after-cmc-issues-stymied-a-once-high-profile-quest/'],[],0,0,2,[],[],https://twitter.com/JohnCendpts/status/1383461285065478158,False,,0,,,,,,,,[],,,,
1383461109240254467,1383461109240254467,2021-04-17 22:13:26 IST,2021-04-17,22:13:26,+0530,102754598,johncendpts,John Carroll,,#4 Harvard billionaire Tim Springer has lined up his latest biotech launch. And he's recruited a star R&amp;D exec to manage their breakthrough game plan  https://t.co/0HP1TvGbBv,en,[],['https://endpts.com/harvard-billionaire-tim-springer-has-lined-up-his-latest-biotech-launch-and-hes-recruited-a-star-rd-exec-to-manage-their-breakthrough-game-plan/'],[],0,0,2,[],[],https://twitter.com/JohnCendpts/status/1383461109240254467,False,,0,,,,,,,,[],,,,
1383460881070100480,1383460881070100480,2021-04-17 22:12:32 IST,2021-04-17,22:12:32,+0530,102754598,johncendpts,John Carroll,,"#3 After being goaded to sell the company, Alexion's CEO set some ambitious new goals for investors. Then Pascal Soriot came calling  https://t.co/wQBX4m7AZj",en,[],['https://endpts.com/after-being-goaded-to-sell-the-company-alexion-set-some-ambitious-new-goals-for-investors-then-pascal-soriot-came-calling/'],[],0,0,0,[],[],https://twitter.com/JohnCendpts/status/1383460881070100480,False,,0,,,,,,,,[],,,,
1383460695182778372,1383460695182778372,2021-04-17 22:11:47 IST,2021-04-17,22:11:47,+0530,102754598,johncendpts,John Carroll,,UPDATED: J&amp;J pauses vaccine rollout as feds probe rare cases of blood clots From @ZacharyBrennan   https://t.co/fBd3ZKpudg,en,"[{'screen_name': 'zacharybrennan', 'name': 'zach brennan', 'id': '605657704'}]",['https://endpts.com/us-pauses-jj-vaccinations-amid-new-reports-of-rare-serious-blood-clots/'],[],0,0,4,[],[],https://twitter.com/JohnCendpts/status/1383460695182778372,False,,0,,,,,,,,[],,,,
1383460598264909833,1383460598264909833,2021-04-17 22:11:24 IST,2021-04-17,22:11:24,+0530,102754598,johncendpts,John Carroll,,By @MaxGelman,und,"[{'screen_name': 'maxgelman', 'name': 'max gelman', 'id': '308763219'}]",[],[],0,0,0,[],[],https://twitter.com/JohnCendpts/status/1383460598264909833,False,https://twitter.com/JohnCendpts/status/1383460409793867782,0,,,,,,,,[],,,,
1383460409793867782,1383460409793867782,2021-04-17 22:10:39 IST,2021-04-17,22:10:39,+0530,102754598,johncendpts,John Carroll,,Top 5 stories of the week: UPDATED: Another big CRO deal has landed as Thermo Fisher acquires PPD for $17.4B  https://t.co/TSryMHs9qd,en,[],['https://endpts.com/another-cro-deal-in-the-works-thermo-fisher-in-talks-to-acquire-ppd-for-15b-report/'],[],0,0,2,[],[],https://twitter.com/JohnCendpts/status/1383460409793867782,False,,0,,,,,,,,[],,,,
1383427008168824837,1383427008168824837,2021-04-17 19:57:56 IST,2021-04-17,19:57:56,+0530,102754598,johncendpts,John Carroll,,Here's @AmberTongPW 's biopharma week in review --  https://t.co/MibSy6ree1,en,"[{'screen_name': 'ambertongpw', 'name': 'amber tong', 'id': '746441781588426752'}]",['https://endpts.com/covid-19-vaccine-halt-drags-on-an-fda-appointment-at-long-last-the-great-cro-consolidation-and-more/'],[],0,2,1,[],[],https://twitter.com/JohnCendpts/status/1383427008168824837,False,,0,,,,,,,,[],,,,
1383425457618444294,1383425457618444294,2021-04-17 19:51:46 IST,2021-04-17,19:51:46,+0530,102754598,johncendpts,John Carroll,,"Thanks, Tim. Much appreciated.",en,[],[],[],0,0,1,[],[],https://twitter.com/JohnCendpts/status/1383425457618444294,False,https://twitter.com/timothyspringer/status/1382837915785572355,0,,,,,,,,[],,,,
1383227129333096452,1383227129333096452,2021-04-17 06:43:41 IST,2021-04-17,06:43:41,+0530,102754598,johncendpts,John Carroll,,"Let's keep in mind that bee stings have killed far more people than the $JNJ vaccine, known to date. Let reason sing.",en,[],[],[],2,6,23,[],['jnj'],https://twitter.com/JohnCendpts/status/1383227129333096452,False,https://twitter.com/rtnarch/status/1383224997888491521,0,,,,,,,,[],,,,
1383206519471185922,1383206519471185922,2021-04-17 05:21:47 IST,2021-04-17,05:21:47,+0530,102754598,johncendpts,John Carroll,,"Oh, God NO! Trump nostalgia? (yes, he's right, but NO)",en,[],[],[],2,0,2,[],[],https://twitter.com/JohnCendpts/status/1383206519471185922,False,https://twitter.com/bydavidcrow/status/1383204837635022848,0,,,,,,,,[],,,,
1383156550655565827,1383156550655565827,2021-04-17 02:03:14 IST,2021-04-17,02:03:14,+0530,102754598,johncendpts,John Carroll,,Been out of action today. I see that $RXRX priced at $16 and promptly shot up 73% today. Just another quiet AI entry.,en,[],[],[],1,0,7,[],['rxrx'],https://twitter.com/JohnCendpts/status/1383156550655565827,False,,0,,,,,,,,[],,,,
1382786711608958976,1382786711608958976,2021-04-16 01:33:37 IST,2021-04-16,01:33:37,+0530,102754598,johncendpts,John Carroll,,#3 Merck scraps their $425M Covid-19 drug in latest pandemic setback $MRK  https://t.co/rUrxXKAbPB,en,[],['https://endpts.com/merck-scraps-their-425m-covid-19-drug-in-latest-pandemic-setback/'],[],0,0,2,[],['mrk'],https://twitter.com/JohnCendpts/status/1382786711608958976,False,,0,,,,,,,,[],,,,
1382786542951796739,1382786542951796739,2021-04-16 01:32:57 IST,2021-04-16,01:32:57,+0530,102754598,johncendpts,John Carroll,,#2  Harvard billionaire Tim Springer has lined up his latest biotech launch. And he's recruited a star R&amp;D exec to manage their breakthrough game plan  https://t.co/0HP1TvGbBv,en,[],['https://endpts.com/harvard-billionaire-tim-springer-has-lined-up-his-latest-biotech-launch-and-hes-recruited-a-star-rd-exec-to-manage-their-breakthrough-game-plan/'],[],0,0,7,[],[],https://twitter.com/JohnCendpts/status/1382786542951796739,False,,0,,,,,,,,[],,,,
1382786370410663937,1382786370410663937,2021-04-16 01:32:16 IST,2021-04-16,01:32:16,+0530,102754598,johncendpts,John Carroll,,Top stories starts with: UPDATED: Another big CRO deal has landed as Thermo Fisher acquires PPD for $17.4B By @MaxGelman   https://t.co/TSryMHs9qd,en,"[{'screen_name': 'maxgelman', 'name': 'max gelman', 'id': '308763219'}]",['https://endpts.com/another-cro-deal-in-the-works-thermo-fisher-in-talks-to-acquire-ppd-for-15b-report/'],[],0,0,0,[],[],https://twitter.com/JohnCendpts/status/1382786370410663937,False,,0,,,,,,,,[],,,,
1382671402524831747,1382671402524831747,2021-04-15 17:55:25 IST,2021-04-15,17:55:25,+0530,102754598,johncendpts,John Carroll,,"I don't do much work on wellness companies, mostly because you hear things like: No one will die from cancer in 10 years.",en,[],[],[],1,1,12,[],[],https://twitter.com/JohnCendpts/status/1382671402524831747,False,,0,,,,,,,,[],,,,
1382670821567565824,1382670821567565824,2021-04-15 17:53:07 IST,2021-04-15,17:53:07,+0530,102754598,johncendpts,John Carroll,,Lots of news about $GSK today -- GlaxoSmithKline’s head of vaccine R&amp;D is jumping to a wellness company concentrating on the microbiome as reports of an exodus start to spread $GSK  https://t.co/5jgWItFSyi,en,[],['https://endpts.com/glaxosmithklines-head-of-vaccine-rd-is-jumping-to-a-wellness-company-concentrating-on-the-microbiome-as-reports-of-an-exodus-start-to-spread/'],[],1,3,6,[],"['gsk', 'gsk']",https://twitter.com/JohnCendpts/status/1382670821567565824,False,,0,,,,,,,,[],,,,
1382658959526432772,1382658959526432772,2021-04-15 17:05:59 IST,2021-04-15,17:05:59,+0530,102754598,johncendpts,John Carroll,,Merck's doing some positioning this morning. The main news: Merck scraps their $425M Covid-19 drug in latest pandemic setback $MRK by @Jasonmmast   https://t.co/rUrxXKAbPB,en,"[{'screen_name': 'jasonmmast', 'name': 'jason mast', 'id': '560452753'}]",['https://endpts.com/merck-scraps-their-425m-covid-19-drug-in-latest-pandemic-setback/'],[],0,1,2,[],['mrk'],https://twitter.com/JohnCendpts/status/1382658959526432772,False,,0,,,,,,,,[],,,,
1382651419967119361,1382651419967119361,2021-04-15 16:36:01 IST,2021-04-15,16:36:01,+0530,102754598,johncendpts,John Carroll,,...Including the latest $GSK oncology setback. And analysts like Geoff Porges are starting to advocate for some major changes  https://t.co/Nbc5PYTqHn,en,[],['https://endpts.com/glaxosmithkline-scraps-two-key-mid-stage-trials-for-their-icos-drug-in-the-latest-setback-for-the-field/'],[],0,0,0,[],['gsk'],https://twitter.com/JohnCendpts/status/1382651419967119361,False,,0,,,,,,,,[],,,,
1382650871947821058,1382650871947821058,2021-04-15 16:33:50 IST,2021-04-15,16:33:50,+0530,102754598,johncendpts,John Carroll,,"we'll have a great morning report out soon, packed with news and people.",en,[],[],[],0,2,10,[],[],https://twitter.com/JohnCendpts/status/1382650871947821058,False,,0,,,,,,,,[],,,,
1382650037461684226,1382650037461684226,2021-04-15 16:30:31 IST,2021-04-15,16:30:31,+0530,102754598,johncendpts,John Carroll,,"This is my favorite story of the week, with Springer interview: Harvard billionaire Tim Springer has lined up his latest biotech launch. And he's recruited a star R&amp;D exec to manage their breakthrough game plan  https://t.co/0HP1TvGbBv",en,[],['https://endpts.com/harvard-billionaire-tim-springer-has-lined-up-his-latest-biotech-launch-and-hes-recruited-a-star-rd-exec-to-manage-their-breakthrough-game-plan/'],[],2,4,13,[],[],https://twitter.com/JohnCendpts/status/1382650037461684226,False,,0,,,,,,,,[],,,,
1382467574575755268,1382467574575755268,2021-04-15 04:25:29 IST,2021-04-15,04:25:29,+0530,102754598,johncendpts,John Carroll,,"Of course, prudence dictates a go slow approach. IN A PANDEMIC. Ya think 3 years from now anyone will think this was incredibly stupid?  https://t.co/0VPQmYsaQS",en,[],['https://www.washingtonpost.com/health/2021/04/14/johnson-and-johnson-vaccine-blood-clots/'],[],0,0,1,[],[],https://twitter.com/JohnCendpts/status/1382467574575755268,False,,0,,,,,,,,[],,,,
1382458804890001408,1382458804890001408,2021-04-15 03:50:38 IST,2021-04-15,03:50:38,+0530,102754598,johncendpts,John Carroll,,"consolidation, thermo the new megaplayer Another big CRO deal in the works? Thermo Fisher in talks to acquire PPD for $15B+ — report by @MaxGelman  https://t.co/TSryMHs9qd",en,"[{'screen_name': 'maxgelman', 'name': 'max gelman', 'id': '308763219'}]",['https://endpts.com/another-cro-deal-in-the-works-thermo-fisher-in-talks-to-acquire-ppd-for-15b-report/'],[],1,4,21,[],[],https://twitter.com/JohnCendpts/status/1382458804890001408,False,,0,,,,,,,,[],,,,
1382453162913669121,1382453162913669121,2021-04-15 03:28:13 IST,2021-04-15,03:28:13,+0530,102754598,johncendpts,John Carroll,,Trying to get a couple of (modest but fairly) significant building projects started in Texas and Vermont. No go. Everyone running and gunning. Car and house prices rising. Get the pandemic over and this economy is going to go off like a bottle rocket,en,[],[],[],1,0,9,[],[],https://twitter.com/JohnCendpts/status/1382453162913669121,False,,0,,,,,,,,[],,,,
1382441696403746820,1382441696403746820,2021-04-15 02:42:39 IST,2021-04-15,02:42:39,+0530,102754598,johncendpts,John Carroll,,"feladilumab, just hanging on -- follows Jounce trounce GlaxoSmithKline scraps two key mid-stage trials for their ICOS drug in the latest setback for the field $GSK  https://t.co/Nbc5PYTqHn",en,[],['https://endpts.com/glaxosmithkline-scraps-two-key-mid-stage-trials-for-their-icos-drug-in-the-latest-setback-for-the-field/'],[],0,0,3,[],['gsk'],https://twitter.com/JohnCendpts/status/1382441696403746820,False,,0,,,,,,,,[],,,,
1382435620237168641,1382435620237168641,2021-04-15 02:18:30 IST,2021-04-15,02:18:30,+0530,102754598,johncendpts,John Carroll,,ICOS going down in flames at $GSK,en,[],[],[],1,0,2,[],['gsk'],https://twitter.com/JohnCendpts/status/1382435620237168641,False,,0,,,,,,,,[],,,,
